Difference between revisions of "Cooper TM, et al. Pediatr. Blood Cancer (2017) cited as Ref 631 in DOI: 10.1038/s41392-020-0110-5 (Q9894)"

From Wikibase.slis.ua.edu
Jump to navigation Jump to search
(‎Created claim: First Author string (P149): Cooper TM, #quickstatements; #temporary_batch_1589996169159)
(‎Created claim: title (P93): A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: a Pediatric O...)
 
(3 intermediate revisions by the same user not shown)
Property / Publication Date
 +
2017
Timestamp+2017-01-01T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 year
Before0
After0
Property / Publication Date: 2017 / rank
 +
Normal rank
Property / Published In Name String
 +
Pediatr. Blood Cancer
Property / Published In Name String: Pediatr. Blood Cancer / rank
 +
Normal rank
Property / Volume
 +
64
Property / Volume: 64 / rank
 +
Normal rank
Property / title
 +
A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: a Pediatric Oncology Experimental Therapeutics Investigators' Consortium study (POE 10-03). (English)
Property / title: A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: a Pediatric Oncology Experimental Therapeutics Investigators' Consortium study (POE 10-03). (English) / rank
 +
Normal rank

Latest revision as of 22:05, 20 May 2020

Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
Language Label Description Also known as
English
Cooper TM, et al. Pediatr. Blood Cancer (2017) cited as Ref 631 in DOI: 10.1038/s41392-020-0110-5
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8

    Statements

    Cooper TM
    0 references
    2017
    0 references
    Pediatr. Blood Cancer
    0 references
    64
    0 references
    A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: a Pediatric Oncology Experimental Therapeutics Investigators' Consortium study (POE 10-03). (English)
    0 references